Intranasal immunization with recombinant Lactococci carrying human papillomavirus E7 protein and mouse interleukin-12 DNA induces E7-specific antitumor effects in C57BL/6 mice

Oncology Letters

Volumn 7, Issue 2, 2014, Pages 576-582

  Li, Yijie ^a   Li, Xinping ^a   Liu, Huanhuan ^a   Zhuang, Shuzhen ^a   Yang, Jianhua ^a,b   Zhang, Fuchun ^a  

^a XINJIANG UNIVERSITY   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antitumor; Co delivery; Human papillomavirus; Intranasal immunization; Lactococcus lactis

Indexed keywords

ANTIGEN; DNA; GAMMA INTERFERON; HUMAN PAPILLOMAVIRUS E7 PROTEIN; INTERLEUKIN 12; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE AMPLIFICATION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LACTOCOCCUS LACTIS; MOUSE; MTT ASSAY; NONHUMAN; POLYMERASE CHAIN REACTION; TUMOR PROTECTION; TUMOR RESISTANCE; VACCINATION; WESTERN BLOTTING;

EID: 84890344768     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1743     Document Type: Article

References (30)

1. Mitragotri S: Immunization without needles. Nat Rev Immunol5: 905-916, 2005.
2. Holmgren J and Czerkinsky C: Mucosal immunity and vaccines. Nat Med 11 (Suppl 4): S45-S53, 2005.
3. Neutra MR and Kozlowski PA: Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-158, 2006.
4. Bermúdez-Humarán LG, Kharrat P, Chatel JM and LangellaP: Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb Cell Fact 10 (Suppl1): S4, 2011.
5. Bahey-El-Din M: Lactococcus lactis-based vaccines from laboratory bench to human use: an overview. Vaccine 30: 685-690, 2012.
6. Wells JM and Mercenier A: Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 6: 349-362, 2008.
7. Moorthy G and Ramasamy R: Mucosal immunisation of mice with malaria protein on lactic acid bacterial cell walls. Vaccine25: 3636-3645, 2007.
8. Villa LL, Costa RL, Petta CA, etal: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol6: 271-278, 2005.
9. Hildesheim A, Herrero R, Wacholder S, etal: Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA298: 743-753, 2007.
10. Boulet G, Horvath C, Vanden Broeck D, Sahebali S and BogersJ: Human papillomavirus: E6 and E7 oncogenes. Int J Biochem Cell Biol 39: 2006-2011, 2007.
11. Bermúdez-Humarán LG, Cortes-Perez NG, Lefèvre F, etal: A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type16-induced tumors. J Immunol 175: 7297-7302, 2005.
12. Jin HS, Park EK, Lee JM, etal: Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor. Gynecol Oncol 97: 559-567, 2005.
13. Lin CT, Tsai YC, He L, etal: DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity. Immunol Lett 114: 86-93, 2007.
14. Hibbitts S: TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases. Curr Opin Mol Ther 12: 598-606, 2010.
15. Wick DA and Webb JR: A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors. Vaccine 29: 7857-7866, 2011.
16. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, etal: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21-26, 1996.
17. Zhang M, Zhang F, Jian X, etal: Cloning and mutation of human papillomavirus type 16 (Xinjiang strain) E7 gene. Biotechnology13: 4-6, 2003 (In Chinese).
18. Tao L, Pavlova SI, Ji X, Jin L and Spear G: A novel plasmid for delivering genes into mammalian cells with noninvasive food and commensal lactic acid bacteria. Plasmid 65: 8-14, 2011.
19. Li YJ, Liu HH and Zhang FC: Co-delivery of exogenous protein and DNA into mammalian cells with Lactococcus lactis. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 28: 1328-1330, 2012 (In Chinese).
20. Audibert F: Adjuvants for vaccines, a quest. Int Immunopharmacol3: 1187-1193, 2003.
21. Dubensky TW Jr and Reed SG: Adjuvants for cancer vaccines. Semin Immunol22: 155-161, 2010.
22. Steidler L, Robinson K, Chamberlain L, etal: Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infect Immun 66: 3183-3189, 1998.
23. Guimarães VD, Innocentin S, Lefèvre F, etal: Use of native lactococci as vehicles for delivery of DNA into mammalian epithelial cells. Appl Environ Microbiol 72: 7091-7097, 2006.
24. Gram GJ, Fomsgaard A, Thorn M, MadsenSM and GlentingJ: Immunological analysis of a Lactococcus lactis-based DNA vaccine expressing HIV gp120. Genet Vaccines Ther 5: 3, 2007.
25. Innocentin S, Guimarães V, Miyoshi A, etal: Lactococcus lactis expressing either Staphylococcus aureus fibronectin-binding protein A or Listeria monocytogenes internalin A can efficiently internalize and deliver DNA in human epithelial cells. Appl Environ Microbiol 75: 4870-4878, 2009.
26. Li YJ, Li Xinping and ZhangFC: The effects of Lactococcus lactis carrying the interleukin-12 (IL-12) gene or recombinant IL-12 protein via different routes mediated antitumor activity. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 29: 392-395, 2013 (InChinese).
27. Cortes-Perez NG, Lefèvre F, Corthier G, Adel-PatientK, LangellaP and Bermúdez-Humarán LG: Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria. Vaccine 25: 6581-6588, 2007.
28. Bermúdez-Humarán LG, Cortes-PerezNG, LeLoirY, etal: An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol 53: 427-433, 2004.
29. Leonard JP, Sherman ML, Fisher GL, etal: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90: 2541-2548, 1997.
30. Huber VC, Arulanandam BP, Arnaboldi PM, etal: Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int Immunopharmacol 3: 801-809, 2003.